Study Evaluating Rapamune in Patients After Kidney Transplantation

Terminated

• Conditions: Renal Transplantation
• Interventions: Drug: sirolimus

• Registration Number: NCT00240214
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions

Detailed Description

Not available

Study Timeline

• Study Start: 2001-04
• Study First Submitted: 2005-10-13
• Study First Submitted QC: 2005-10-13
• Study First Posted: 2005-10-17
• Primary Completion: 2008-02
• Study Completion: 2008-02
• Status Verified: 2008-03
• Last Update Submitted: 2008-03-13
• Last Update Posted: 2008-03-14

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Patients having received a renal allograft from a cadaveric or living donor with low or moderate risk of developing acute rejection episodes.

Read More

Exclusion Criteria

• Contraindications according to Summary of the Product Characteristics (SmPC).

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	sirolimus	sirolimus